Aripiprazole or Bupropion Augmentation Versus Switching to Bupropion in Treatment-Resistant Depression
The Journal of Clinical Psychiatry · 2025
DOI: 10.4088/jcp.25m15863 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Psychiatry, 2025. Verfasst von William U Meyerson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Precision Psychiatry, Massachusetts General Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Bupropion, Aripiprazole, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NLM NIH HHS.
Themen: Depression
Abstract (Originalsprache)
Objective
In treatment-resistant depression (TRD), augmentation with aripiprazole (A-ARI) or combination therapy by adding bupropion (C-BUP) has been reported as more effective than switching to bupropion (S-BUP), but C-BUP risks falls in older adults, and A-ARI risks weight gain and tardive dyskinesia (TD). The aim of this study was to clarify whether the enhanced effectiveness outweighs such risks.
Methods
In this risk-benefit decision analysis, lifetime quality-adjusted life-years (QALYs) following 1 year of A-ARI or C-BUP vs S-BUP treatment were simulated in a health-state transition model tracking depression remission, falls, weight gain, and TD, in age and baseline body mass index (BMI) subgroups, using data from the VAST-D and OPTIMUM trials and other literature. QALYs were converted to depression-free day-equivalents (DFDs), the QALYs gained from 1 day of remitted versus active depression.
Results
Simulated adults aged 18-64 years experienced a net benefit of C-BUP over S-BUP of 20.7 DFDs, equivalent to about 3 weeks of faster remission of depressive symptoms. In older adults, especially those aged 85+ years, this benefit over S-BUP was partially but not fully offset by a risk of falls. In adults aged 18-64 years, A-ARI was estimated to offer only 8.0 DFDs after subtracting the expected harms from TD, and this was further reduced to -22.8 DFDs once metabolic harms were considered, in those overweight at baseline. Overall, C-BUP was preferred over A-ARI in all subgroups except ages 85-89 years with BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Precision Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
- Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts.
- Corresponding Author: William U. Meyerson, MD, PhD, Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Simches Research Center, 185 Cambridge St, Boston, MA 02114 (wmeyerson@mgh.harvard.edu…
- Department of Psychiatry, Larner College of Medicine, University of Vermont, Burlington, Vermont.
- Harvard Medical School, Boston, Massachusetts.
- Department of Psychology and Neuroscience, Duke University, Durham, North Carolina.
Förderung
- NIMH NIH HHS
- NLM NIH HHS
Zitieren
APA
Meyerson, W. U., Ross, E. L., Kennedy, C. J., Hoyle, R. H., Chhatwal, J., Wang, P. S., & Smoller, J. W. (2025). Aripiprazole or Bupropion Augmentation Versus Switching to Bupropion in Treatment-Resistant Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.25m15863
Vancouver
Meyerson WU, Ross EL, Kennedy CJ, Hoyle RH, Chhatwal J, Wang PS, et al. Aripiprazole or Bupropion Augmentation Versus Switching to Bupropion in Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 2025. doi:10.4088/jcp.25m15863
BibTeX
@article{Meyerson2025,
author = {Meyerson, William U and Ross, Eric L and Kennedy, Chris J and Hoyle, Rick H and Chhatwal, Jagpreet and Wang, Philip S and Smoller, Jordan W},
title = {Aripiprazole or Bupropion Augmentation Versus Switching to Bupropion in Treatment-Resistant Depression},
journal = {The Journal of Clinical Psychiatry},
year = {2025},
doi = {10.4088/jcp.25m15863}
}
EUVIMED